{"id":34483,"date":"2023-10-17T13:50:26","date_gmt":"2023-10-17T11:50:26","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=34483"},"modified":"2023-10-17T13:50:27","modified_gmt":"2023-10-17T11:50:27","slug":"the-springboard-doctrine-in-the-context-of-patent-law-part-two-managing-ip-2023","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/de\/publikationen\/the-springboard-doctrine-in-the-context-of-patent-law-part-two-managing-ip-2023\/","title":{"rendered":"The springboard doctrine in the context of patent law \u2013 part two, Managing IP 2023"},"content":{"rendered":"\n<p>Zum Abschluss einer zweiteiligen Serie geht <a href=\"https:\/\/www.maiwald.eu\/de\/team\/marco-stief\/\" data-type=\"link\" data-id=\"https:\/\/www.maiwald.eu\/de\/team\/marco-stief\/\">Dr. Marco Stief<\/a> tiefer in die Materie ein, um ihre Voraussetzungen zu erl\u00e4utern, die Rechtsprechung zu \u00fcberpr\u00fcfen und ihre Relevanz f\u00fcr den Pharma- und Biowissenschaftssektor zu untersuchen.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-34483","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/34483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":2,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/34483\/revisions"}],"predecessor-version":[{"id":34485,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/34483\/revisions\/34485"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/media?parent=34483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}